Published in Health and Medicine Week, October 10th, 2005
This was the conclusion of data presented for the first time at the European Federation of Neurological Societies (EFNS) annual congress.
A new clinical study shows that zolmitriptan nasal spray (ZNS) achieved the primary endpoint of headache relief at 30 minutes with significantly higher response compared to placebo (60% ZNS 10mg, 38% ZNS 5mg vs. 21% placebo; p<0.001),(1) demonstrating a reduction from moderate, severe or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.